Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30040160 | 1.00 | CNR2 (0.41) | CNR2FAAHGPR119PRKDCIRAK4 | |
| SCHEMBL24961373 | 0.95 | CNR2 (0.43) | CNR2FAAHGPR119PRKDCIRAK4 | |
| SCHEMBL30040347 | 0.95 | CNR2 (0.43) | CNR2FAAHGPR119PRKDCIRAK4 | |
| SCHEMBL28765810 | 0.78 | ELANE (0.41) | CNR2FAAHGPR119PRKDCIRAK4 | |
| SCHEMBL24961371 | 0.75 | KDM4E (0.47) | CNR2FAAHPIK3CA | |
| SCHEMBL30952921 | 0.75 | KDM4E (0.47) | CNR2FAAHPIK3CA | |
| SCHEMBL28767224 | 0.74 | CNR2 (0.41) | CNR2FAAHGPR119PRKDCIRAK4 | |
| SCHEMBL23626191 | 0.71 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL30952890 | 0.71 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL14824496 | 0.71 | FAAH (0.44) | FAAHGPR119PRKDCIRAK4ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113767090-B | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230021669-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021136244-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021669-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP4A11, CYP4F11, CYP11B2 | CNR2 719/4885FAAH 335/4885GPR119 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.